Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

Dr. Mikhail Fedyanin on Mutation Discordance and Liquid Biopsy in CRC

November 5th 2016

Mikhail Fedyanin, MD, PhD, Russian Academy of Medical Science, discusses mutation discordance in the primary tumor and metastases in patients with colorectal cancer (CRC), as well as the benefits of liquid biopsy.

Dr. Maria Ignez Braghiroli on Impact of Tumor Side in mCRC

October 28th 2016

Maria Ignez Braghiroli, MD, medical oncologist, Instituto do Câncer do Estado de São Paulo, discusses clinical characteristics and outcomes of patients with metastatic colorectal cancer (CRC) harboring NRAS mutations.

Dr. Braghiroli on the Current and Future Treatment Landscape in CRC

October 26th 2016

Maria Ignez Braghiroli, MD, medical oncologist, Instituto do Câncer do Estado de São Paulo, discusses what the current treatment landscape looks like for patients with colorectal cancer, as well as what the future may hold.

Dr. Heinemann on the Use of Depth of Response and RECIST in CRC

October 24th 2016

Volker Heinemann, MD, PhD, director of the Comprehensive Cancer Center at Ludwig Maximilian University of Munich, compares the use of depth of response and RECIST criteria to measure responses in patients with colorectal cancer.

Study Explores Mutation Discordance Between Primary, Metastatic Sites in CRC

October 20th 2016

Mutation discordance between primary and metastatic sites in colorectal cancer may occur more often than previously understood, opening the door for potential new therapeutic approaches to treating the disease.

Left-Sided CRC Survival Advantage May Be Dependent on Stage

October 19th 2016

The correlation between tumor location and improved survival varies based on stage of disease in patients with metastatic colorectal cancer.

Dr. Mikhail Fedyanin on Mutation Discordance in CRC

October 19th 2016

Mikhail Fedyanin, MD, PhD, Russian Academy of Medical Science, discusses mutation discordance in the primary tumor and metastases in patients with colorectal cancer (CRC).

Dr. Pietrantonio on the Design and Rationale Behind a Nomogram to Predict Survival Rates in CRC

October 18th 2016

Filippo Pietrantonio, MD, Department of Medical Oncology, Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan Fondazione IRCCS Istituto Nazionale dei Tumori, discusses a nomogram that can predict 12-week survival rates for patients with colorectal cancer.

Dr. Braghiroli on Individualization of Treatment in CRC

October 13th 2016

Maria Ignez Braghiroli, MD, medical oncologist, Instituto do Câncer do Estado de São Paulo, discusses the ways in which treatment can be individualized for patients with colorectal cancer depending on the mutations they may harbor.

Expert Sheds Light on Identifying "Lynch-Like Syndrome" in Patients With dMMR Rectal Cancer

October 12th 2016

To properly manage patients with DNA mismatch repair deficiency rectal cancer, one must have a well-rounded understanding of the molecular and clinical causes and risks associated with this subgroup of patients.

Dr. Venook on Looking Ahead at Treatment for CRC

October 11th 2016

Alan P. Venook, MD, The Madden Family Distinguished Professor of Medical Oncology and Translational Research at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses future steps for treatment of patients with colorectal cancer.

Dr. Berger on Benefits of New Screening Test for CRC

October 11th 2016

Barry M. Berger, MD, FACP, chief medical officer, Exact Sciences, discusses Cologuard screening test for colorectal cancer (CRC).

Dr. Braghiroli on Clinical Characteristics of NRAS-Mutant CRC

October 9th 2016

Maria Ignez Braghiroli, MD, medical oncologist, Instituto do Câncer do Estado de São Paulo, discusses clinical characteristics and outcomes of patients with NRAS-mutant metastatic colorectal cancer (mCRC) during an interview at the 2016 ESMO Congress.

Dr. Heinemann on Implications of SIRFLOX Study for mCRC

October 7th 2016

Volker Heinemann, MD, PhD, director of the Comprehensive Cancer Center at Ludwig Maximilian University of Munich, discusses the broad clinical implications of the SIRFLOX findings for patients with metastatic colorectal cancer (mCRC).

Dr. Matthew Yurgelun on Pathogenic Mutations in CRC

September 22nd 2016

Matthew B. Yurgelun, MD, Targeted Oncology, Yurgelun, Instructor in Medicine, Harvard Medical School, discusses a recent study which uncovered BRCA1 and BRCA2 mutations as possible risk markers for colorectal cancer.

Dr. Paty on High-Risk Period for Rectal Tumor Regrowth

September 21st 2016

Philip B. Paty, MD, surgeon, Memorial Sloan Kettering Cancer Center, discusses the high-risk period for rectal tumor regrowth in patients.

Dr. Bekaii-Saab on Differences Between Regorafenib and TAS-102 in CRC

September 20th 2016

Tanios Bekaii-Saab, MD, professor of Medicine, Mayo Clinic, discusses regorafenib and TAS-102. In colorectal cancer.

Dr. Bekaii-Saab on Microsatellite Instability in Colorectal Cancer

September 16th 2016

Tanios Bekaii-Saab, MD, professor of Medicine, Mayo Clinic, discusses microsatellite instability in colorectal cancer.

Prognostic Tool for Immuno Age Debuts

September 6th 2016

An assay that would evaluate the immune status of patients with colon cancer is poised to become the first of a series of Immunoscore tests for various tumor types.

Obesity an Increasing Incidence in Breast Cancer, CRC Survivors

September 3rd 2016

Obesity is more prevalent in cancer survivors, specifically in those with a history of breast or colorectal cancer, compared with those without any history of disease.